The appeal comes four years after the Afghan veteran was sentenced at Joint Base Lewis-McChord (JBLM) in Western Washington for one of the most notorious U.S. war crimes of recent decades.
WASHINGTON — Army Staff Sgt. Robert Bales has asked an Army court for a special hearing to explore evidence that his massacre of 16 Afghan civilians may have been tied to a controversial malaria drug given to troops that is known to cause hallucinations, anxiety and paranoia.
During a hearing Tuesday at Fort Belvoir, Virginia, an expert for Bales, former Army public-health physician Dr. Remington Nevin, submitted affidavits arguing that Bales likely experienced hallucinations and psychosis related to either taking mefloquine, also known by the brand name Lariam, in Afghanistan or previously in Iraq.
The prescription was not considered during the investigation, and his legal team is using this in a request for the U.S. Army Court of Criminal Appeals to review Bales’ life sentence without parole in the killings that took place March 11, 2012, in Kandahar province.
Mefloquine is a malaria-treatment medication that was commonly used by the U.S. military as a prophylactic in malaria-endemic regions, taken once a week by troops. It has been controversial since its commercial introduction in 1989, as it is known to cause neurological and vestibular problems in a small percentage of users.
Most Read Nation & World Stories
- The little-noticed surge across the U.S.-Mexico border: Americans heading south VIEW
- Can 'Jeopardy!' whiz James Holzhauer be beat? The science of memory and recall, explained
- Trump's sanctions on Iran are hitting Hezbollah hard
- Morehouse College graduates’ student loans to be paid off by billionaire
- Oregon college safety officer pleads guilty to killing woman
Concerns inside the Defense Department began surfacing in 2002 after a string of violent deaths and suicides among soldiers and military family members at Fort Bragg, N.C. In 2004, a federal investigation found that 11 service members taking the medication experienced debilitating vertigo.
In 2009, the Defense Department issued a policy listing it as a last-choice preventive, to be used only in areas where strains are resistant to other medications.
And in 2012 and 2016, several case studies were published of troops developing brain damage as a result of taking the drug.
The U.S. Army Court of Criminal Appeals in Northern Virginia comes four years after Bales was sentenced at Joint Base Lewis-McChord (JBLM) in Western Washington for one of the most notorious U.S. war crimes of recent decades.
Shortly after Bales murdered the Afghan civilians on March 11, 2012, retired Army psychiatrist Col. Elspeth Cameron Ritchie raised questions as to whether Bales had been taking mefloquine during his deployment or on his previous three trips to Iraq.
The next month, in April 2012, the Food and Drug Administration received notification from Roche, the maker of the brand-name version of mefloquine, that it had received a report from an anonymous pharmacist that a patient taking the medication had developed homicidal behavior that “led to the homicide killing of 17 Afghans.” (Initial reports cited that 17, not 16, villagers had been killed.)
“It was reported that the patient was suffering from traumatic brain injury and was administered mefloquine in direct contradiction to U.S. military rules that mefloquine should not be given to soldiers who had suffered traumatic brain injury due to its propensity to cross blood-brain barriers inciting psychotic, homicidal or suicidal behavior,” the report stated.
Bales had sustained a traumatic brain injury during his last deployment to Iraq, in 2009.
The FDA disclosed the adverse report in 2013 as Bales was being sentenced, having pleaded guilty in exchange for dropping the death penalty. The lead prosecutor in the case, now-retired Army Lt. Col. Jay Morse, told McClatchy that the document, referenced in news stories, was not known to the prosecution as evidence and there was nothing in Bales’ health records on mefloquine prescriptions.
In January 2012, then Assistant Secretary of Defense for Health Affairs Dr. Jonathan Woodson issued a memo noting that some deployed service members were issued mefloquine without its being recorded in their medical records.
In his clemency request in 2014, Bales cited post-traumatic stress disorder, his brain injury, alcohol and steroid use while deployed, as well as his reliance on sleeping pills and steroids he took as possible contributing factors.
He also spoke of guilt, fear and the desire to protect his fellow soldiers all as factors.
“I still don’t believe that the PTSD, TBI, alcohol, steroids and sleeping pills were the only factors in my actions on March 11, 2012. I believe there is much more,” he wrote.